Article Figures & Data
Figures
- Figure 1.
Growth inhibition of GLM-1 cells by afatinib and lapatinib in vitro. A: Immunohistochemical analysis of HER2 expression in GLM-1 xenografts. Inset: HER2 gene amplification detected by FISH. Comparison of growth inhibition of GLM-1 cells by lapatinib and afatinib. *p<0.01, **p<0.001 (vs. lapatinib). Bars: standard error (SE). B: Quantification of the cell-cycle fractions is shown. C: Annexin V assay. The percentage of cells in the right lower quadrant (annexin V+/PI- cells) are shown as early apoptotic cells. D: Western blot analysis of EGFR, HER2 and HER3, and their downstream signaling mediators Akt and Erk in GLM-1cells.
- Figure 2.
Anti-tumor and anti-metastatic effects of lapatinib, afatinib, and trastuzumab on GLM-1 tumors. A: Effects on the growth of s.c. GLM-1 xenografts in nude mice. *p<0.05, **p<0.001 (vs. control). Bars: SE. B: Body weight changes in nude mice. C: Effects on GLM-1 peritoneal metastasis. Representative images of peritoneal metastases (left). Quantification of the anti-metastatic effects of the drugs (right). *p<0.01, **p<0.001 (vs. control). Bars: SE.
- Figure 3.
Growth inhibition of trastuzumab-resistant cells (GLM-1HerR2) by lapatinib and afatinib in vitro and in vivo. A: Cell-cycle and apoptotic analysis of GLM1-HerR2 cells. Quantification of the cell-cycle fractions (left). Quantification of apoptosis (right). B: Growth inhibition of GLM-1HerR2 cells in vitro. *p<0.01 (afatinib vs lapatinib). Bars: SE. C: Western blot analysis of EGFR, HER2, HER3, Akt and Erk1/2 in GLM-1HerR2 cells treated with lapatinib or afatinib in vitro. D: Anti-tumor effects of lapatinib and afatinib alone and in combination with trastuzumab in sc tumor-bearing mice. *p<0.05, **p<0.01, ***p<0.001 (vs. control). NS: Not significant. Bars: SE.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.